The name of our company defines our services, strengths, and values. Since the inception, we have endeavoured to research, analyze and present the critical market data with great attention to details.
Breast cancer is one of the most common and leading causes of cancer deaths among women worldwide. The widespread use of hormone replacement therapy (HRT), following menopause, increased mammographic screening, and diet changes are majorly responsible for the rise in breast cancer incidence rates. According to WHO, breast cancer is the most frequent cancer among women, affecting 2.1 million women each year. In 2018, it is estimated that ~15% of all cancer deaths among women were due to breast cancer.
According to Global Cancer Observatory (GLOBOCAN), the number of new breast cancer cases was increased by 26.5% from 1,651,326 in 2012 to 2,088,849 in 2018. Further, these numbers are expected to increase to 2,407,748 and 2,853,857 new cases by 2025 and 2035, respectively. Similarly, breast cancer deaths are also expected to increase by more than 44%, from 626,679 in 2018 to 904,805 by 2035. Therefore, due to this increase, the adoption and emergence of new technologies for breast cancer screening, detection, and diagnosis is rising globally.
In recent years, increasing awareness among women has alerted them to seek medical advice and regular checkups. Also, nowadays, various organizations are carrying out awareness programs and campaigns to detect breast cancer. For instance:
- In the U.S., National Breast Cancer Foundation, Inc. provides free mammograms and diagnostic services for early diagnosis and treatment of breast cancer.
- In China, the government has implemented a population-based cancer screening program to reduce the mortalities related to breast, cervical, and colorectal cancers. The program also aimed to gather information about the cost-effectiveness of breast cancer treatment for high-risk women.
Moreover, continuous investments in healthcare facilities to equip better instruments and focus of key players towards developing regions have further offered high opportunities for players operating in the breast imaging market.
- In July 2019, Cancer Research UK and SV Health Investors (U.S.) collaborated with an investment of $249.5 million (£200 million) to help companies focus on cancer diagnosis and treatment.
- In July 2019, the French government announced the “Ma santé 2022" plan to reform the country's healthcare system.
Thus, the increasing prevalence of breast cancer are expected to drive the global breast imaging market over the coming years.
Meticulous Research’s Repository for Breast and Medical Imaging Industry Include:
Breast Imaging Market by Technology [Ionizing (FFDM, Analog, 3D Mammogram, CT, CBCT), Non-Ionizing (Breast Ultrasound, Breast MRI, AWBU, Breast Thermography)], End User (Hospital, Diagnostic Imaging Center), and Geography - Forecast to 2027
Interventional oncology Market by Procedure [Embolization (TARE, TACE), Ablation (Thermal Ablation (Microwave, RF Ablation))], Product [Embolization (SIR-Spheres, TheraSpheres)], Application (Liver, Lung, Breast), and End User - Global Forecast to 2025
Radiotherapy Market by Product (Radiotherapy Devices, Software, Service), Procedure (EBRT, Brachytherapy, Systemic Radiotherapy), Technology (IMRT, SRT, VMAT, HDRBT, LDRBT, PDRBT), Application (Prostate, Breast) - Global Forecasts to 2025
Ultrasound Market by Product (Devices, Probes), Technology (FUS, SWL), Display (Color, B/W), Portability (Trolley, Compact, Handheld, Point of Care), Application (Diagnostic, Therapeutic, Orthopedic), End User (Hospitals, ACC) - Global Forecast to 2024
An electronic health record (EHR) is an electronic version of a patient's medical history that is maintained over time by the provider and may include all of the key administrative, clinical data relevant
Over the past few years, there has been a significant rise in funding for universities conducting R&D in microscopes. These fundings allow the universities or academic institutions to set up new
Continuous bioprocessing, already conventional in many manufacturing fields, has established itself in biopharma, which is